Replies to post #312 on BSD Med Corp. (fka PRSNQ)

[surf1944]

9:16AM BSD Medical reports publication of clinical study results of hyperthermia using the BSD-2000 and chemotherapy to treat advanced pancreatic cancer patients; hyperthermia, delivered using the BSD-2000, combined with gemcitabine and cisplatin resulted in low toxicity and high feasibility (BSDM) 1.48 : Co announced the publication of results from a clinical study on advanced pancreatic cancer using the BSD-2000 Hyperthermia System (BSD-2000). The study reported the results of a retrospective analysis of 23 patients with advanced or metastatic pancreatic cancer who had relapsed after first-line chemotherapy treatment. The researchers, Tschoep-Lechner, et al., reported that hyperthermia, delivered using the BSD-2000, combined with gemcitabine and cisplatin resulted in low toxicity and high feasibility, even in these study patients who had a very negative prognosis and no standard treatment options. The researchers also reported that, despite the intrinsic limitation of a small retrospective analysis, the results suggested clinical efficacy of hyperthermia combined with gemcitabine and cisplatin whereas gemcitabine and cisplatin without hyperthermia does not seem to provide a significant benefit in patients with advanced pancreatic cancer.